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Background: Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation
of a lysosomal hydrolase, the enzyme α-galactosidase A (GLA). This inactivation is responsible for the storage
of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction.
The incidence of disease is estimated at 1:40,000 in the general population, although neonatal screening
initiatives have found an unexpectedly high prevalence of genetic alterations, up to 1:3,100, in newborns in Italy,
and have identified a surprisingly high frequency of newborn males with genetic alterations (about 1:1,500) in
Taiwan.
Case presentation: We describe the case of a 40-year-old female patient who presented with transient ischemic
attack (TIA), discomfort in her hands, intolerance to cold and heat, severe angina and palpitations, chronic kidney
disease. Clinical, biochemical and molecular studies were performed.
Conclusions: Reported symptoms, peculiar findings in a renal biopsy – the evidence of occasional lamellar
inclusions in podocytes and mesangial cells – and left ventricular (LV) hypertrophy, which are considered to be
specific features of FD, as well as molecular evaluations, suggested the diagnosis of a classical form of FD.
We detected four mutations in the GLA gene of the patient: -10C>T (g.1170C>T), c.370-77_-81del
(g.7188-7192del5), c.640-16A>G (g.10115A>G), c.1000-22C>T (g.10956C>T). These mutations, located in promoter
and intronic regulatory regions, have been observed in several patients with manifestations of FD. In our patient
clinical picture showed a multisystemic involvement with early onset of symptoms, thus suggesting that these
intronic mutations can be found even in patients with classical form of FD.
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Fabry disease is a rare pathology caused by mutations in
the gene encoding the enzyme α-galactosidase A, a lyso-
somal hydrolase which detaches the galactose bound in α
from globotriaosylceramide (Gb3) during glycosphingoli-
pid metabolism [1]. The alteration of this process leads
to the accumulation of Gb3 inside lysosomes of different
cell types, with consequent cellular damage, giving rise to
the phenotype of FD.* Correspondence: duro@ibim.cnr.it
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reproduction in any medium, provided the orRecent studies suggest that FD is under-diagnosed in
the general population. Neonatal screening studies have
found a surprisingly high incidence of genetic altera-
tions, 1:3,100, among infants in Italy and 1:1,500 among
newborn males in Taiwan [2,3]. In the latter study, 86%
had an intronic mutation, c.936+919G>A, that is asso-
ciated with an atypical form of FD which is characterized
by residual enzyme activity [3].
The classical form of FD is characterized by acropar-
esthesias and angiokeratomas in childhood, severe skin
manifestations in adolescence, and progressive organ in-
volvement with renal failure, cardiac and cerebrovascular
disease in adulthood [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Electron microscopy on a renal biopsy from a 40-year-
old woman with FD. Typical lysosomal inclusions in tubular cells
are shown (arrow).
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ranging from no disease to more severe clinical forms,
due to random X-chromosome inactivation (Lyonization)
[5].
Atypical forms of FD are characterized by symptoms
affecting a single, specific organ, especially the heart,
kidney and brain [6,7]. These renal, cardiac, or cerebro-
vascular variants manifest later in life, and are often
associated with residual enzyme activity. Cases that
should be considered among the possible atypical var-
iants of FD include those in which the coding regions of
the gene are wild type but there are single nucleotide
substitutions and small deletions present in the regula-
tory and intronic regions. Some of these mutations can
be considered polymorphisms, since they are present in
more than 1% in the general population.
This paper presents the results of a study conducted on
a woman with clinical symptoms related to FD. In our pa-
tient the typical picture of FD with a multisystemic in-
volvement, the early onset of symptoms and molecular
evaluations suggest that the presence of mutations in pro-
moter and regulatory intronic regions of the GLA gene
can be found even in patients with classical form of FD.
Case presentation
A 40-year-old female presented as an outpatient with
chronic kidney disease. At 23 years old, she had been hos-
pitalized for a TIA and was diagnosed with vasculitis. Oc-
casionally, she had experienced discomfort in her hands
and feet that was triggered by warm or cold temperatures.
At age 27, several other TIA episodes occurred. When
the patient was 37, she was hospitalized for an episode of
severe angina and palpitations. At that time, a transthor-
acic echocardiography was performed that showed con-
centric LV hypertrophy, with an end-diastolic septal wall
thickness of 14 mm, a normal ejection fraction of 53%,
and impaired diastolic function; in addition, hypokinesia
of the infero-lateral wall was observed. Further evaluation
included a myocardial scintigraphy with Tc-99 m-MIBI
that showed a persistent defect at the level of the infero-
lateral region of the LV, consistent with the diagnosis of
myocardial infarct. The patient suffered another TIA epi-
sode during the period of hospitalization. Furthermore,
the patient presented proteinuria with value of 1.2 g/
24 hrs, normal blood pressure (130/70 mmHg), serum
creatinine levels of 2.3 mg/dl, a glomerular filtration rate
of 35 ml/min, serum Urea of 71 mg/dl, serum albumin of
4.2 g/dl. Anti-nuclear antibodies (ANA), Coombs test,
antibodies anti-platelets and anti-granulocytes were nega-
tive. The patient also reported that she had undergone
two normal pregnancies. Her family medical history was
negative.
In order to evaluate the nature of the persistent pro-
teinuria and the impaired renal function, the patientunderwent a renal biopsy. Optical microscopy of the
glomeruli (38–61) showed collapse in 4–6 of them and
glomerular sclerosis in the others (data not shown). The
interstitium showed a chronic inflammatory infiltrate
and focal areas of tubular atrophy; residual tubules
showed epithelial vacuolization and focal fibrosis. Im-
munofluorescence was negative for IgA, IgG, IgM,
kappa and lambda chains, C3, C4, C1q, and fibrinogen.
An electron microscopy study (Figure 1) showed several
typical lysosomal inclusions in tubular cells, podocytes
and mesangial cells, which are histological hallmark of
FD [8].
To further characterize cardiac morphology, the patient
underwent a cardiovascular magnetic resonance (CMR)
study using a 1.5-T MRI system (Gyroscan Intera, Philips
Medical Systems) equipped with high performance gradi-
ents. After a survey scan was obtained, a breath-holding
T2-weighted black blood multiecho multishot turbo spin-
echo (TSE) sequence with four different TEs was used to
obtain images of the four-chamber horizontal long-axis
plane for myocardial T2 relaxation time (MT2RT) mea-
surements. LV four-chamber horizontal long-axis images
were acquired using a breath-holding 3D balanced turbo
field-echo multiphase multislice sequence; subsequently,
biventricular short-axis images were obtained for evalu-
ation of LV mass. MT2RT and LV mass were calculated
as previously described [9,10]. There was a significantly
prolonged MT2RT throughout the entire LV myocardium
(Figure 2). A prolongation of MT2RT throughout the en-
tire myocardium may be observed in patients with FD
[9,10]. Researchers have shown that factors such as myo-
cardial water and lipid alterations can lead to an abnormal
prolongation of the MT2RT and to an increase in signal
intensity [11]. Therefore, it is reasonable to presume that
the prolonged MT2RT in all myocardial regions, as
observed in this case, was related to the marked glycolipid
deposition in the myocardium. Our patient showed an
Figure 2 Four-chamber horizontal long-axis T2-weighted black
blood turbo spin-echo MR image. White circles outline regions of
interest in the mid septum, apex, and infero-lateral wall. MT2RTs
were 82 milliseconds in mid septum, 84 milliseconds in apex, and 85
milliseconds in infero-lateral wall.
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ventricular septal wall thickness of 14 mm and postero-
lateral wall thickness of 15 mm (Figure 3).
As a result of the renal biopsy and cardiac MRI study
findings, associated to the clinical history, suggesting FD,
the patient underwent enzymatic and genetic analyses of
α-galactosidase A. Enzymatic analysis was performed
using the Dried Blood Filter Paper test (DBFP) described
by Chamoles et al., with minor modifications [12]. The
patient showed almost a normal value of α-galactosidase
A activity in the blood; nevertheless, this value give noFigure 3 Four-chamber horizontal long-axis balanced fast field
echo image. There is evidence of LV concentric hypertrophy.clear indication of FD because the subject affected is a
female. As an X-linked genetic disorder, FD was first
thought to affect only men and women were generally
considered to be asymptomatic carriers. However, recent
studies suggest that female heterozygotes for FD may
still develop vital organ damage causing severe morbidity
and mortality.
Genetic analysis was performed by high resolution melt-
ing (HRM) analysis on DNA samples, isolated from whole
blood, using the Light Cycler 480 system [13]. PCR pro-
ducts presenting melting curves different in position or
shape from those of the wild type control were sequenced
to identify the suspected mutations. DNA sequencing has
identified the presence of four previously reported muta-
tions, combined in a heterozygote haplotype -10C>T
(g.1170C>T), c.370-77_-81del (g.7188-7192del5), c.640-
16A>G (g.10115A>G), c.1000-22C>T (g.10956C>T),
mapping in promoter and regulatory intronic regions
[14-18]. These intronic mutations could play both quali-
tative and quantitative roles in the transcription of the
gene and in the translation of α-galactosidase A, a hy-
pothesis strengthened in some cases by the presence of
Gb3 and/or lyso-Gb3 in the blood and urine of patients
[18]. It has been shown that regulatory intronic regions
may regulate the splicing of the corresponding mRNA,
and that mutations in these regions, or factors that act
in trans with them, can cause genetic diseases [19,20].
After these findings, the patient underwent to enzyme
replacement therapy with agalsidase alfa, the efficacy of
which is due to its ability to reverse lysosomal glycosphin-
golipid accumulation. Due to the short period of treat-
ment, to date patient’s symptoms have not improved but
disease progression was arrested.
Conclusions
In this paper, we reported the case of a 40-year-old female
patient in which clinical history and specific instrumental
findings suggested the diagnosis of FD. A genetic survey
found four intronic mutations, in heterozygosis, in posi-
tions -10C>T (g.1170C>T), c.370-77_-81del (g.7188-
7192del5), c.640-16A>G (g.10115A>G), c.1000-22C>T
(g.10956C>T) in the GLA gene. These mutations have
been observed in several patients with manifestations of
FD characterized by not severe clinical picture, with
symptoms affecting a specific organ, and that occur later
in life because residual enzyme activity remains high
enough to prevent organ damage in childhood and ado-
lescence. In our patient multisystemic involvement and
early onset of symptoms seems to suggest a classical
form of FD, without any mutations in coding region of
the GLA gene but presenting a combined heterozygote
intronic haplotype. Our results and those recently
reported in the literature support the idea that FD is not
only caused by genetic alterations in the exons of GLA,
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tion [3]. It has been shown that aberrant splicing of the
messenger is the cause of at least 15% of human genetic
diseases, stressing the importance of studying also in-
tronic regions of the genes involved [21].
Since non-coding regions are not routinely evaluated
when sequencing the GLA gene, the occurence of intronic
disease-causing lesions should encourage to analyze them
and to perform, in patients with such mutations, further
clinical and instrumental evaluations. This can lead to
confirm diagnosis of FD in a higher number of patients,
thus providing a more realistic estimation of the preva-
lence of FD in general population.
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